INTRODUCTION
The generation of immunity requires collaboration between dendritic cells (DCs) and T cells, as the priming of cytotoxic T lymphocyte (CTL) by DCs is a crucial event in the fight against infection and tumors 1 . DCs regulate immune responses by recognizing, processing, and decoding pathogen associated molecular patterns (PAMPs) and antigenic molecules [2] [3] [4] [5] [6] . PAMP recognition by pattern recognition receptors (PRRs) present intercellularly or at the DC surface signal the presence of infection and triggers signal transduction pathways ultimately resulting in DC activation [4] [5] [6] . Generally, activated DCs are characterized by enhanced expression of MHC and co-stimulatory molecules and proinflammatory cytokines, which enables DCs to translate pathogenic signals to naïve T cells and trigger adaptive immune responses [2] [3] [4] [5] [6] [7] [8] . Recent studies have demonstrated that DCs may act as a network of distinct subsets that each perform specialized functions to stimulate and polarize T cell responses in order to coordinate immune regulation [9] [10] [11] [12] [13] [14] [15] . Antigen processing and presentation to T cells is predominantly attributed to the conventional DC subset (cDCs), consisting of both CD8(-) DCs and CD8(+) DCs. CD8(+) DCs are especially adept at cross-presentation of exogenous antigen, IL-12 production and induction of cytotoxic T cell responses [16] [17] [18] [19] [20] . The plasmacytoid DC (pDC) subset has the capacity to produce significant amounts of type-1 interferons (IFNs) in response to microbial nucleic acids, particularly during viral infection, to facilitate T cell activation, growth and survival for disease clearance [13] [14] [15] 21 . Moreover, the processes mediated by pDC and CD8(+) DC subsets have been associated with priming T-helper 1 (Th1) effector cells for the control of infection and tumors. A balanced distribution of activated DC subsets is associated with the control of autoimmune disease and tumors, indicating that these cells may cooperate during the generation of protective immunity 9, 10, 12, 13 . Currently, cancer vaccines are designed to introduce antigen in combination with adjuvants to activate DCs either ex vivo prior to administration, or in situ 7, 8, [21] [22] [23] [24] . A range of stimuli are used to trigger innate immunity resulting from DC maturation, including proinflammatory cytokines, PAMPs recognized by the toll-like receptor (TLR) family, and feedback signals from innate and adaptive immune cells. Discrete combinations of these stimuli and DC subsets may differentially control T cell activation and polarization, and these components may be optimized and exploited to generate effective immune responses that eradicate tumors or infectious agents. However, it is currently unclear what components and DC subsets should be included in cancer vaccines, partly because current techniques limit the cell types that can be cultured or targeted [21] [22] [23] [24] . Standard DCbased protocols used in the clinic utilize monocyte-derived conventional DCs that are unable to cross-present antigens, or efficiently produce IL-12 or type-1 IFNs to prime CTL-mediated immune responses and tumor cell death [22] [23] [24] . There have been efforts to utilize type 1 differentiated DCs in combination with TLR agonists to boost CTL priming capacity, but this ex vivo maturation is accompanied by decreased migratory and stimulatory function upon implantation 22 .
Previously, we described macroporous polymer matrices that regulate the trafficking and activation of DCs in vivo by precisely controlling the presentation of GM-CSF and CpG-oligonucleotide (CpG-ODN) adjuvants [25] [26] . When applied as cancer vaccines, these matrices led to CTL-mediated eradication of melanoma tumors 26 . Here, these matrices were modified to present 3 different classes of TLR agonists, CpG-ODN, monophosphoryl lipid A (MPLA), and polyinosinic:polycytidylic acid (P(I:C)), all in combination with GM-CSF. We hypothesized that PLG matrices presenting various combinations of adjuvants would modulate the distribution of DC subsets at the vaccine site, and influence the development of immunity to antigens loaded within these vaccine systems. This approach would then allow us to identify critical cellular and molecular hallmarks for effective vaccination or immunotherapy. Therefore, we first quantified the ability of various adjuvants to generate activated DC subsets and cytokines in vivo. The impact of DC induction on T cell-mediated immunity and cancer vaccine efficacy with models of B16-F10 melanoma was next assessed. These studies demonstrated that antitumor efficacy requires CD8(+) DCs and is strongly correlated with pDC numbers.
Survival outcomes were also correlated to an array of inflammatory cytokines, which revealed a strong relationship between IL-12 and G-CSF production and antitumor efficacy. Altogether, these studies demonstrate that one can recruit and utilize various DC subsets for in situ vaccination, and provide important cellular and molecular insights into cancer vaccine design.
MATERIALS & METHODS
Cell Culture. B16-F10 melanoma cells were obtained from American Type Culture Collection (catalog: ATCC CRL-6475) in 2010 and 2012. Upon receipt, the cells were cultured to passage three, aliquoted and frozen in liquid nitrogen. For tumor experiments, B16-F10 cells were thawed and cultured in DMEM (Life Technologies, Inc.), containing 10% fetal bovine serum (Life Technologies, Inc.), 100 units/ml penicillin, and 100 μg/ml streptomycin. The cells were maintained at 37°C in a humidified 5% CO 2 /95% air atmosphere and early passage cells (between 4 and 9) were utilized for experiments. The cells have not been reauthenticated since receipt.
Mice. C57BL/6 mice (6-8-week-old female; Jackson Laboratories), B6.129S2-Cd8atm1Mak/J (CD8 T cell KO; 6-8-week-old female; Jackson Laboratories), (Alkermes, Cambridge, MA) was utilized in a gas-foaming process to form porous PLG matrices 27 . In brief, PLG microspheres encapsulating GM-CSF were first made using standard double emulsion 28 . The double emulsion process was also utilized to fabricate PLG microspheres containing MPLA (Avanti Polar Lipids, Alabaster, AL) as an adjuvant 41 . PLG microspheres were then mixed with 150 mg of the porogen, sucrose (sieved to a particle size between 250 μm and 425 μm), and compression molded. The resulting disc was allowed to equilibrate within a high-pressure CO 2 environment, and a rapid reduction in pressure causes the polymer particles to expand and fuse into an interconnected structure 27 . The sucrose was leached from the scaffolds by immersion in water, yielding scaffolds that were 80-90% porous.
B6.129P2(SJL)-
To incorporate tumor lysates into PLG scaffolds, biopsies of B16-F10 tumors that had grown subcutaneously in the backs of C57BL/6J mice (Jackson Laboratory, Bar
Harbor Maine), were digested in collagenase (250 U/ml) (Worthington, Lakewood, NJ) and suspended at a concentration equivalent to 10 7 cells per ml after filtration through 40 μm cell strainers. The tumor cell suspension was subjected to 4 cycles of rapid freeze in liquid nitrogen and thaw (37°C) and then centrifuged at 400 rpm for 10 min. The supernatant (1ml) containing tumor lysates was collected, incubated with the PLG microspheres and lyophilized. The resulting mixture was used to make PLG scaffoldbased cancer vaccines.
To incorporate CpG-ODNs and P(I:C) into PLG scaffolds, CpG-ODN 1826, 5'-tcc atg acg ttc ctg acg tt-3', (Invivogen, San Diego, CA) or P(I:C) (high molecular weight; Invivogen, Sand Diego, CA) was first condensed with poly(ethylenimine) (PEI, Mn ~60,000, Sigma Aldrich) molecules by dropping CpG-ODN 1826 or P(I:C) solutions into a PEI solution, while vortexing the mixture 29 . The charge ratio between PEI and CpG-ODN (NH3+:PO4-) was kept constant at 7 during condensation. The charge ratio between PEI and P(I:C) (NH3+:PO4-) was kept constant at 3 during condensation. The condensate solutions were then vortexed with 60 μl of 50% (wt/vol) sucrose solution, lyophilized and mixed with dry sucrose to a final weight of 150 mg.
The sucrose containing PEI-CpG-ODN condensate was then mixed with blank, GM-CSF and/or tumor lysate loaded PLG microspheres to make PLG cancer vaccines.
In Vitro Release Studies. To determine the efficiency of GM-CSF incorporation and the kinetics of GMCSF release from PLG scaffolds, 125I-labeled hr-GM-CSF (Perkin Elmer) was utilized as a tracer. Scaffolds were prepared with iodinated GM-CSF and placed in 3 ml of Phosphate Buffer Solution (PBS) in an incubator (37°C). At various timepoints, the PBS release media was collected and replaced with fresh media. The amount of 125I-hr-GMCSF released from the scaffolds was determined at each time point by counting the radioactivity of the removed media in a gamma counter and normalizing the result to the total 125I-GM-CSF incorporated into the scaffolds. The total amount of CpG-ODN incorporated into PLG scaffolds and released into PBS over time was determine by using an oligreen assay (Invitrogen).
In addition, the MPLA incorporation and release was determined by dissolving the matrix in a 2:1 chloroform:methanol mixture. The solution was vigorously shaken for 10 minutes and evaporated under a stream of N2. One milliliter of 3N methanolic HCl, 1ml of hexane, and 25µl of a 10mg/ml pentadecanoic acid internal standard stock solution was added to each reaction vessel. The vessels were capped tightly and heated at 50°C for 3hours. The samples were allowed to cool for 10 minutes and then 1ml each of water and hexane was added. The reaction vessels were vigorously shaken for 5 minutes and allowed to phase separate. One microliter of the hexane layer was sampled for the gas chromatography-mass spectrometry analysis. The MPLA content was then quantified by detecting the total methyl ester derivative of myristic acid.
In situ identification of DCs and T cells. GM-CSF loaded PLG matrices and matrices containing GM-CSF in combination with either 100ug of CpG-ODN, MPLA, or P(I:C) were implanted into subcutaneous pockets on the back of 7-9 week old male C57BL/6J mice. To analyze DC recruitment, scaffolds were excised at various time-points and the ingrown tissue was digested into single cell suspensions using a collagenase solution (Worthington, 250 U/ml) that was agitated at 37°C for 45 minutes. The cell suspensions were then poured through a 40μm cell strainer to isolate cells from scaffold particles and the cells were pelleted and washed with cold PBS and counted using a Z2 coulter counter (Beckman Coulter). To assess, DC infiltration and activation, subsets of the total cell population isolated from PLG matrices were then stained with primary antibodies (BD Pharmingen, San Diego, CA) conjugated to fluorescent markers to allow for analysis by flow cytometry. APC-conjugated CD11c (dendritic cell marker), FITC-conjugated MHCII and PE-conjugated CD86 (B7, costimulatory molecule) stains were conducted for DC recruitment and activation analysis. To further delineate the presence of specific DC subsets, cells were also stained with APC-conjugated CD11c and PE-conjugated PDCA-1 (plasmacytoid DC marker) or APC-conjugated CD11c and PE-conjugated CD8 (CD8 DCs). DC subsets were classified as CD8(+)CD11c(+) DCs (CD8+ DCs) and CD11c(+)CD8(-)PDCA-1(+) (pDCs). To track dendritic-cell emigration from the implant site, FITC was incorporated into the scaffolds 25, 31 . To assess T cell infiltration PE-Cy7 conjugated CD3 stains were performed in conjunction with APC-conjugated CD8a (CD8 T cells), and PE-conjugated FoxP3 (Treg) and analyzed with flow cytometry. Statistical significance of differences between the groups were analyzed by a Student's t test and a P value of less than 0.05 was considered significant. Macroporous, poly-lactide-co-glycolide (PLG) matrices ( Fig 1A) were designed to quickly release GM-CSF 25 . Approximately 60% of the protein was released by day 10 (Fig 1B-D) , to induce the recruitment of DCs or their precursors. GM-CSF loaded PLG scaffolds were also modified to present TLR-activating, CpG-ODN, MPLA and P(I:C) molecules, as danger signals. The in vitro release kinetics of GM-CSF were similar in all conditions, irrespective of which TLR agonist was included in the vaccine (Fig 1B-1D ).
RESULTS

Controlled GM-CSF and TLR Agonist Presentation
TLR agonists were more stably associated with scaffolds than was GM-CSF, as only 20-30% of incorporated CpG-ODN, P(I:C) and MPLA were released over the first 10 days in vitro, followed by slow and sustained release of danger signals over the next 14 days.
Presentation of the TLR agonists in this system was designed to provide a long-term, local signal to activate DCs. Importantly, the relatively high molecular weight and composition of the particular PLG chosen to fabricate scaffolds results in slow scaffold degradation 31 , allowing for long-term analysis of the vaccine site and its regulation over DC activation and T cell immunity.
Controlled DC generation and activation in vivo
To examine the ability of PLG matrices to recruit and activate dendritic cells in vivo, matrices delivering GM-CSF in combination with danger signals were implanted subcutaneously into the backs of C57BL/6J mice. The magnitude of DC infiltration and activation into the matrices was determined by FACS analysis of cell populations subsequently isolated from the polymeric material after 7 days. Control matrices delivering GM-CSF alone contained 2.4 + 0. Because LN-homing of DCs is a critical factor in generating immunity we investigated the ability of TLR agonists to promote DC emigration from PLG matrices to the draining lymph nodes. As utilized in previous reports, fluorescein isothiocyanate (FITC) was incorporated into PLG scaffolds as a model antigen, as dendritic cells recruited to the scaffold will ingest this label 30 . The label can be later used to identify these cells following their trafficking to the inguinal lymph nodes. At day 2, MPLA stimulation led to a significantly higher overall number of scaffold-derived DCs in the inguinal lymph nodes as compared to controls and scaffolds containing CpG-ODN or P(I:C) as a stimulant (2B). However, at later timepoints, day 4 and 7 after implantation, the number of DCs induced to home to LN by MPLA subsided to control levels (Fig 2B) , whereas CpG-ODN or P(I:C) stimulation resulted in a significantly higher number of DCs. At day 7 after implantation, CpG and P(I:C) loaded matrices resulted in more than a 10-fold increase in LN DCs over control conditions and MPLA stimulation (Fig 2B) , and these results were consistent with the DC activation observed at the vaccine site ( Fig   S1 and S2) . These data indicate that CpG-ODN or P(I:C) agonists, as presented from PLG matrices, were able to promote greater and sustained lymph node homing as compared to MPLA or control conditions. Interestingly, stimulation of the cells which infiltrated PLG matrices with CpG-ODN, MPLA or P(I:C) enriched the numbers of CD11c(+)PDCA-1(+) pDCs and CD11c(+)CD8(+) cDCs (Fig. 3A) relative to controls. The danger signals increased the numbers of pDCs at the implant site by approximately 4-fold relative to control matrices, with an average pDC number of 140,000 cells residing in the scaffolds presenting any of the TLR agonists (Fig 3A) . CD8(+) DCs were also present at the implant site at approximately 5-fold higher levels with MPLA and P(I:C) presentation, and at a 9-fold higher number when utilizing CpG-ODN as a stimulant. Strikingly, the local delivery of TLR-activating agents promoted the local production of IL-12 (200-400 ng/ml) at the implant site (Fig 3B) , with CpG and P(I:C) inducing the highest levels. The IL-12 concentration correlated with the increased numbers of activated DCs and DC subsets in these conditions (Fig. 3A) . Additionally, the concentrations of a panel of candidate inflammatory cytokines were assayed at the vaccine site (Table S1 & S2; Fig S3) .
Elevated levels of IFN-α (Fig S3) resulted from CpG-ODN and P(I:C) presentation, while MPLA had no effect on IFN-α concentration. However, MPLA led to 4-fold higher levels of TNF-α (Table S1 & Fig S4) . Interestingly, IL-12 concentrations at MPLA loaded matrices were 2-fold lower than found in CpG-ODN and P(I:C) loaded matrices. TNF-α may inhibit monocyte and DC derived IFN-γ, IL-12 and T cell 
matrices might be less efficient at stimulating anti-tumor T cell responses compared to matrices incorporating CpG-ODN and P(I:C).
Prophylactic vaccination and correlates to its efficacy
Since PLG matrices presenting TLR agonists generate distinct and activated DC populations in situ and potent cytokine production, the anti-tumor efficacy of these systems was tested in the poorly immunogenic, B16-F10 melanoma model. (Fig. 5B) . Regression analysis was subsequently performed to determine whether induction of long-term survival was related to pDC, CD8(+) (Fig   4A&B) , and cytokine levels (Table S2) at the vaccine site: previously published data using various doses of CpG-ODN 26 were included in the analysis. Strikingly, animal survival rates were strongly correlated with the numbers of pDCs, CD8(+) DCs and with endogenous IL-12 and G-CSF generated by PLG vaccines (Fig 4A-D; Table S2 ). These findings suggest that the important parameters potentiating vaccine efficacy include cross-presentation by CD8(+) DCs, and cooperative mechanisms promoted by pDCs and the cytokines, IL-12 and G-CSF.
Moreover, TLR-MyD88 and TLR-TRIF are critical signaling pathways regulating cytokine production and immune responses 33 , and a complete loss of prophylactic 
vaccine efficacy was observed when utilizing vaccines in TRIF and MyD88 knockout mice, regardless of the TLR agonist (Fig S5) . Although P(I:C) is thought to be TRIFdependent (TLR3), CpG MyD88 dependent (TLR9), and MPLA (TLR4) can activate via TRIF and MyD88, it is likely that TLR agonists presented within tumor cell lysate and polymeric formulations require both pathways to promote the appropriate cytokine production and cellular regulation that actuates effective vaccination.
Therapeutic vaccination and anti-tumor cytotoxic T cell activity
As specific vaccine formulations containing various TLR agonists produced significant numbers of activated DCs and conferred prophylactic immunity, it was (Fig. 5A & B) . PLG vaccines presenting MPLA as an adjuvant decreased the rate of tumor progression (Fig. 5A) , and a slight increase in mean survival time (~1.5 fold increase) over controls was found ( Figure 5A and 5B). Complete tumor regression (Tumors < 36 mm compared with control animals (Fig. 5C-D) . CD8(+) T cell infiltrates were further characterized for co-expression of IFNγ and CD107a, a marker for cytotoxic-associated cell degranulation. These cell populations were markedly enhanced in vaccine treated animals (Fig 5C-D) . Vaccines featuring CpG-ODN, P(I:C) and MPLA signaling resulted in approximately 6.1, 3.1 and 1.4 fold increases in IFNγ(+), CD107a(+) TILs in comparison to controls. Moreover, CpG loaded vaccines resulted in significantly higher numbers of activated TILs in comparison to their P(I:C) and MPLA counterparts ( Fig   5D) .
The activation of systemic CTL responses was also monitored by staining splenocytes with MHC class I/TRP2 peptide pentamers to identify CTLs with specificity to tyrosinase-related protein (TRP)-2. This is a main antigenic target of melanoma vaccines in mice and humans. A significant expansion of TRP2 specific CTLs was observed in the spleens of mice vaccinated with CpG-ODN, MPLA and P(I:C) loaded vaccines, in comparison to controls devoid of TLR agonists (Fig. 5E) . Analysis of cells infiltrating the vaccines incorporating TLR agonists also revealed a significant, local CD3(+)CD8(+) T cell response (Fig. S6) , likely in response to sustained tumor antigen presentation.
Vaccination of transgenic mice lacking CD8(+) T lymphocytes resulted in
decreased levels of IL-12 and IFN-γ ( Fig. S7 and S8) , in comparison to wild-type. The IL-12-IFNγ pathway is a positive feedback mechanism, with each cytokine augmenting production of its counterpart 32, 34 ; these data suggest that the immune responses induced by this vaccine system may be amplified by cytokine mediated cross talk between DCs and primed CTLs. To investigate whether the potent anti-tumor efficacy induced by P(I:C) and CpG could translate to other tumor settings, we tested these systems in the lewis lung carcinoma (LLC) model. The P(I:C) and CpG agonists were used because these agonists induced the highest survival rates in B16 melanoma models. Similar to the results in the B16 prophylactic model, P(I:C) and CpG vaccines loaded with LLC tumor cell lysates prophylactically promoted 80 and 70% survival (Fig 5G) . Also, in therapeutic models 
Vaccine efficacy is impaired in mice lacking CD8(+) DC
Since PLG vaccines incorporating TLR agonists were capable of generating were not protected and tumor growth rates were similar to unvaccinated, wild-type animals (Fig 6A) . Moreover, , as a 3 fold reduction in Trp2 specific CTLs was measured in the spleens of these mice in comparison to wild-type controls (Fig 6D) . These results indicate that vaccine efficacy in this system is critically regulated by CD8 DCs, potentially via their ability to cross present tumor antigens, to produce Th-1 induction factors such as IL-12, and to generate and interact with CTLs.
Because our regression analysis identified IL-12, G-CSF and IL-6 as strong correlates to survival (Table S2) , we investigated whether the presence of CD8(+) DCs effected induction of these cytokines by PLG vaccines. Wild type mice were able to induce the production of the T cell growth factor, IL-12, at the vaccine site at 5-fold higher levels than found in vaccinated Batf3 -/-mice ( Fig 6C) . The partial loss of IL-12 production in CD8(+) DC knock-out mice suggests that these cells are important producers or mediators of this Th1-polarizing cytokine. Similarly, knocking out the CD8(+) DC population resulted in approximately 3-fold decreases in the levels of IL-6 and G-CSF at the vaccine site ( Fig. S10 and S11 ). These cytokines are associated with priming innate immunity and danger signal activation, including TLR signaling, suggesting these mechanisms of DC stimulation are compromised in Batf3-/-mice.
DISCUSSION
To address the limitations of current cancer vaccines, we utilized a PLG matrix controlling the presentation of tumor lysate, GM-CSF and TLR agonists to create a vaccine node that recruits and activates multiple DC subsets in situ. This tool was used to investigate the contribution of DC subsets to vaccine efficacy and demonstrated that effective tumor cell killing required the participation of CD8(+) DCs, with strong correlations to pDC number and IL-12, G-CSF, and IL-6 concentrations. This study expands on previous reports, by demonstrating that these components were critical to vaccine efficacy, regardless of the type of stimulant incorporated within the scaffolds.
As described previously, GM-CSF delivery was utilized to promote DC recruitment to the vaccine site where these cells are subsequently activated by TLRagonist presentation. We determined that vaccines were able to maintain elevated levels of GM-CSF for at least 14 days regardless of the TLR agonist incorporated into the system. Interestingly, GM-CSF concentrations at the vaccine site at day 14 were approximately 80-110 fold higher than would be expected solely from release from the vaccine, as determined by in vitro release kinetics. The absolute concentrations were also lower than control matrices with only GM-CSF (Table S1 ). The assay is not able to distinguish between exogenous and endogenous GM-CSF and cellular infiltrates may differentially produce and consume GM-CSF at the vaccine site in response to local vaccine activity (Table S1) .
In this report, we now describe methods to incorporate different classes of TLR 
agonists into biomaterial vaccine systems and control their presentation. Inclusion of TLR stimulation was required to significantly upregulate DC co-expression of MHCII and CD86 (Fig 2) , enhancing their capacity to propagate antigen-specific T cell populations. Appropriate TLR signaling increased the generation of CD8(+) and pDC subsets at the vaccine site, and stimulated the production of IFNs and the potent T cell growth factor, IL-12. Moreover, removal of TLR agonists from the system resulted in decreased numbers of Trp2 specific, cytotoxic CD8(+) T cells locally at the vaccine site and systemically in spleens and tumors, and this coincided with reduced survival in vaccine studies.
Interestingly, a recent report described the sequestration of tumor specific, CD8(+) T cells at the site of vaccines with persistent antigen presentation. In that study, this resulted in dysfunctional immune responses and local T cell apoptosis relative to relatively non-persistent vaccine formulations 34 . In contrast to those peptide-based vaccines, the system in this report was fabricated to present whole tumor cell lysates within controlled inflammatory microenvironments to confer an immuno-stimulatory and tumor-mimicking microenvironment, which produced significant, antigen specific T cell infiltration at both the vaccine site and the tumor environment ( fig 5C, 5D 
vaccinated animals demonstrated intense and activated CD8(+), cytotoxic T cell infiltrates ,as determined by CD107a and IFN-γ expression, likely effecting tumor-cell killing. Although the PLG vaccines were able to induce prophylactic and therapeutic survival in B16 models, unlike peptide in mineral oil formulations, the findings by Hailemichael et al. 34 suggest that we could further improve efficacy by utilizing more degradable PLG formulations that may reduce the duration of antigen presentation to focus the induced T cell response on tumors.
These systems outperformed the preclinical, historical results of current vaccine modalities extensively studied in the clinic, including irradiated tumor cell vaccines and DC-based vaccines 7,8,26,36,37, . Also, vaccines containing CpG-ODN and P(I:C) stimulation were able to confer efficacious anti-tumor responses in both prophylactic and therapeutic LLC models indicating that these results are transferrable to other tumor settings.
Interestingly, vaccines presenting MPLA signaling slowed tumor growth rates but did not cause tumors to completely regress. The current vaccine design is able effectively exploit CpG-ODN and P(I:C) signaling, as compared to MPLA, to promote higher average levels of cell surface activation markers on DCs and cytokine profiles that promote Th-1 polarization and CTL responses. Additionally, MPLA was a strong inducer of TNF-α, in comparison to CPG-ODN and P(I:C) (Fig S2) , and this may inhibit IL-12, and IFN pathways priming CTL responses 32, 34 . It is important to note that these results do not definitively address the potency of TLR4 antagonism relative to TLR3 and 38, 39 . CD8(+) DCs and IL-12 can cause Treg inhibition or their conversion to IFNγ producing, effector T cells [40] [41] [42] , and these mechanisms are potentially critical to the efficacy of these material-based cancer vaccines. Surprisingly, another cytokine, G-CSF, was found to be a strong correlate of vaccine efficacy (Table S2 ) even though it has been associated with suppression of T cell proliferation and cytolytic effectors [43] [44] [45] . G-CSF, however is a strong mobilizing factor for mononuclear cells and DCs, and its elevated endogenous production may combine with vaccines presenting TLR ligands to enhance DC differentiation and activation, and antitumor responses 46, 47 .
An interesting aspect of this vaccine system is CTL homing to the vaccine site ( 
